Blossomhill Therapeutics, Inc.

I’ve sat in boardrooms where the science was strong, the clinical data looked clean, and the business case still didn’t hold together. In almost every case, the missing piece was regulatory strategy, or more precisely, the absence of regulatory strategy as both a governance conversation and a core driver of enterprise value.

Regulatory Affairs has traditionally been brought into the conversation later than it should. Bringing it in earlier, as a strategic thought partner rather than a final compliance step, is where boards can unlock meaningful value in the development programs.

Why Boards Deprioritize It

Most boards don’t dismiss regulatory strategy on purpose. They deprioritize it because it looks like a compliance function with its own specialized language, and specialized functions tend to get delegated rather than debated. That’s a mistake. Regulatory strategy isn’t a translation layer between the science and the agency. It’s one of the few functions that touches timeline, cost and competitive positioning all at once, which makes it a business decision disguised as a technical one.

Regulatory Strategy Is Capital Allocation Strategy

Every board grapples with the same question: where should we deploy limited capital for the greatest return? In biopharma and medtech, the honest answer is that the regulatory pathway, not just the science, often determines the return on investment.

I’ve watched an oncology program move from “interesting” to “fundable” the moment a credible, regulator-tested pathway was mapped against the clinical data package. A single-arm trial design paired with a wellsupported accelerated approval strategy shaved years off the development timeline and materially changed the riskadjusted value of the asset.

There is a real difference between a regulatory update slide and a regulatory strategy conversation. The former tells the board what happened. The latter helps the board decide what to do next.

I’ve seen the device-side version of this too: a diagnostic platform that qualified for breakthrough device designation used that status to secure earlier, more substantive FDA feedback on its evidence plan, which meant less rework and a faster route to a submission the agency had effectively already previewed. In both cases, the regulatory pathway wasn’t a formality behind the business case. It was the business case.

Regulatory Foresight Is Boardroom Risk Governance

Global development means navigating divergent expectations. What satisfies the FDA does not automatically satisfy PMDA or EMA, and discovering that gap after a pivotal trial or device validation study has already been designed is a costly way to learn it.

When regulatory foresight is built into strategic planning early, boards catch these divergences in time to design around them: harmonized endpoints for drugs, sound predicate strategies or clinical bridging for devices, and sequencing decisions that keep multiple markets in play. This is risk governance in the truest sense, and it belongs alongside the financial and operational risk conversations boards already have.

From Regulatory Reporting to Regulatory Input

There is a real difference between a regulatory update slide and a regulatory strategy conversation. The former tells the board what happened. The latter helps a board decide what to do next: which indication or device configuration to prioritize, whether to pursue a breakthrough therapy or breakthrough device designation now or wait for more mature data, and how a designation might reshape the competitive and commercial timeline.

When regulatory leaders are brought into portfolio and prioritization discussions as strategic partners, rather than looped in after a decision is already made, the entire organization moves faster and with more conviction.

The One Change That Matters Most

Boards don’t need a longer checklist. They need one structural change: give the most senior regulatory voice in the organization a standing seat in strategic and portfolio discussions, not just a periodic reporting slot. Everything else, from succession planning to how regulatory complexity gets communicated upward, follows naturally once that seat exists.

Companies that consistently turn scientific innovation into approved, marketed therapies and devices aren’t the ones with the best science alone. They’re the ones who stopped asking regulatory affairs what happened and started asking it what should happen next.